Anti_human P504S rabbit polyclonal
- Known as:
- Anti_human P504S host: rabbit pab
- Catalog number:
- ASA905-508
- Product Quantity:
- 1 mL
- Category:
- -
- Supplier:
- Other suppliers
- Gene target:
- Anti_human P504S rabbit polyclonal
Related genes to: Anti_human P504S rabbit polyclonal
- Gene:
- AMACR NIH gene
- Name:
- alpha-methylacyl-CoA racemase
- Previous symbol:
- -
- Synonyms:
- RACE, P504S
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-19
- Date modifiied:
- 2016-12-13
Related products to: Anti_human P504S rabbit polyclonal
Related articles to: Anti_human P504S rabbit polyclonal
- Tubulocystic renal cell carcinoma (TC-RCC) is a rare and distinct subtype of renal cell carcinoma with characteristic histopathological and immunohistochemical features. Due to its rarity, limited data exist regarding its clinicopathological profile, biological behavior, and prognosis. This review aims to analyze reported TC-RCC cases to improve understanding of tumor characteristics, outcomes, and key diagnostic markers. - Source: PubMed
Publication date: 2026/05/21
AbuHaweeleh Mohannad NAlhyari AbdelkareemAbuhayeh NadaEmam FatimaAl-Qudimat Ahmed RAl Rumaihi KhalidKhalil Ibrahim A - gene alterations are significant drivers in a subset of renal cell carcinomas (RCCs), associated with high-grade morphology, aggressive behavior, and features overlapping with biphasic hyalinizing psammomatous RCC (BHP RCC). We report two examples of -mutated RCC to advance understanding of this entity. Both were female patients in their sixth decade with incidental, solid renal masses (3.2 and 3.0 cm). Both tumors had high-grade nuclei and infiltrative growth but distinct architectures: tumor #1 showed solid nests, tubules, and a focal BHP RCC-like biphasic pattern; tumor #2 featured solid, elongated tubulotrabeculae with spindling and peritubular basement membrane material. Both had sclerotic stroma. Immunohistochemistry showed positivity for PAX8, keratin 7, vimentin, and AMACR (tumor #2: focal TFE3). Targeted next-generation sequencing identified pathogenic somatic mutations in both tumors: a nonsense mutation (c.235A>T, p.Lys79*) in tumor #1 (validated by Sanger sequencing) and a splice-site mutation (c.600-1G>A) with concurrent chromosome 22 deletion (confirming biallelic inactivation) in tumor #2. Subsequent merlin immunohistochemistry showed loss of expression. / rearrangements were absent. Patient #1 developed widespread metastases within 7 months and received immunotherapy; patient #2 remains disease-free at short-term follow-up. These tumors highlight the broad morphological heterogeneity within -mutated RCC and underscore the necessity of an integrated diagnostic approach combining histology, immunohistochemistry (especially merlin loss), and molecular confirmation. Recognizing this entity is critical for accurate classification and for guiding potential therapeutic strategies, including immune checkpoint inhibitors. - Source: PubMed
Publication date: 2026/05/06
Zhao MingWang JuanjuanWang SuyingFang RongZhang HuizhiLiu Yiyu - Accurate risk stratification, essential for the therapeutic approach (especially surgical) of prostate cancer, is based on standard histopathological criteria. The biological heterogeneity of this neoplasm requires the identification of complementary markers that reflect the molecular mechanisms of tumor progression. The aim of this study was to evaluate the correlation between immunohistochemical markers of metabolism (AMACR, NKX3.1) and proliferation (Ki-67) and histopathological aggressiveness in ADK (prostate adenocarcinoma). This retrospective, single-center clinicopathological study included 385 patients with prostatic lesions from Sf. Apostol Andrei Emergency Clinical Hospital in Constanta (2023 2024). Of these, 198 cases of ADK were selected for the main immunohistochemical analysis. The cases were classified according to the Gleason system and Grade Groups. The expression of AMACR, NKX3.1 and Ki-67 markers was assessed by immunohistochemistry and correlated with Grade Groups, as well as with the presence of chronic inflammation and peritumoral glandular atrophy. Increased AMACR expression (93.9% of cases) and increased Ki-67 index ( 20% in 29.3% cases) were significantly correlated with high Grade Groups (p 0.001). Loss of NKX3.1 expression increased from Grade Group 1 to Grade Group 4, followed by a lower frequency in Grade Group 5, indicating a non-linear association with histopathological grade (p for trend 0.001). The concomitant presence of chronic inflammation and glandular atrophy was associated with high Grade Groups and with a significantly higher Ki-67 index (p=0.001 and p 0.001). Triple staining (AMACR/p63/HMWCK) showed no discordant cases in distinguishing ADK from benign lesions that mimic prostate cancer. The extended immunohistochemical profile (AMACR, NKX3.1, Ki-67) provides valuable biological information correlated with tumor aggressiveness. Integrating these markers into the preoperative evaluation, along with standard histopathological evaluation and the peritumoral microenvironment, may contribute to a more accurate risk stratification. However, these findings are correlative, and their clinical applicability requires validation through further prospective studies. - Source: PubMed
Roşu Mihai-CătălinEnciu ManuelaAşchie MarianaIonescu Cristina AnitaPundiche MihaelaDobrin NicolaeȘtefanov ConstanţaNicolau Antonela-AncaNicoleta LeopaCaraban BogdanDeacu SorinBălţătescu Gabriela-IzabelaBulbuc IonuţPopovici Ion AlexandruPetcu Lucian Cristian - To study the clinicopathological features, immunophenotype, diagnosis, and prognosis of TSC/mTOR mutation-associated renal cell carcinoma with leiomyomatous stroma (M/TSC-RCC-LMS). Nine cases of molecularly confirmed M/TSC-RCC-LMS were collected at the Affiliated Hospital of Qingdao University (7 cases) and No. 971 Hospital of the People's Liberation Army, Qingdao, China (2 cases) between December 2011 and August 2024. Histological evaluation, immunohistochemical staining, and molecular analysis were performed, along with literature review. Among the 9 patients, 1 was male and 8 were female, with their ages 48(35,55) years. Eight cases were detected during routine physical examinations, while 1 case presented with painless gross hematuria. All 9 cases were located within the renal parenchyma, presenting nodular masses with tumor diameters 2.0(1.4,2/7) cm. The lesions were well-circumscribed. The tumors were solid, grayish-white, grayish-yellow or grayish-red in color, and soft in consistency, while one case showed cystic-solid characteristics. All 9 cases exhibited thick fibromuscular pseudocapsules. In 8 cases, smooth muscle components within the capsule were observed extending into the tumor, dividing the neoplastic tissue into nodular and clustered patterns. The tumor cells were primarily arranged in tortuous, elongated branching tubular structures, with focal areas showing small amounts of delicate papillary structures containing fibrovascular cores. They also had abundant cytoplasm that was pale-staining or mildly eosinophilic, occasionally clear. The nuclei were round or irregular in shape, with some showing conspicuous nucleoli. All the 9 cases showed patchy to diffusely strong expression of CK7 (70%-100%). Carbonic anhydrase Ⅸ (CAⅨ, 6/9) and CD10 (membranous positivity, 8/9) demonstrated variable extent and intensity of expression. Glycoprotein nonmetastatic melanoma protein B (GPNMB) showed diffusely moderate to strong positivity in 7 of the 9 cases. The 9 cases were all negative for α-methylacyl-CoA racemase (AMACR), TFE3, TFEB, TCEB1, HMB45, and Melan A, with Ki-67 proliferative index ranging from 1% to 10%. Whole exome sequencing revealed mTOR gene mutations in 5 cases, concurrent TSC2 and mTOR mutations in 1 case, a TSC2 mutation in 1 case, and germline TSC1 mutations in 2 cases. Follow-up of the cases ranged from 6 to 159 months. All patients were alive at the end of the follow-up, with no recurrence or metastasis. M/TSC-RCC-LMS exhibits unique morphological and immunophenotypic characteristics. The tumor cells exhibit abundant pale or mildly eosinophilic cytoplasm, forming elongated, tortuous branching tubules accompanied by stromal smooth muscle components. These are typically morphological features of this renal cell carcinoma subtype. The contribute to the diagnosis and differential diagnosis of the tumor diffusely strong positivity of CK7 and the positivity of GPNMB. This type of renal cell carcinoma often demonstrates indolent biological behaviors with favorable prognosis and is expected to be newly classified as an independent subtype of renal cell carcinoma. - Source: PubMed
Han M HChu JWang YGuo Z HLiu YYu W JLi Y JZhang WJiang Y X - The Extracellular Vesicles Gene-based Prostate Score (EGPS), powered by DeepSeek, is an artificial intelligence (AI) diagnostic tool that enhances the detection of clinically significant prostate cancer (csPCa) using urinary EV-derived gene expression, without requiring digital rectal examination (DRE). To address overdiagnosis resulting from the limited specificity of prostate-specific antigen (PSA) and reduce unnecessary biopsies, this study evaluated the clinical utility and generalizability of EGPS in men undergoing initial biopsy with PSA levels ranging from 0 to 15 ng/mL. A total of 645 patients were retrospectively enrolled: 586 from three centres were divided into training (70%) and internal validation (30%) cohorts, and 59 from two centres served as the external validation cohort. EVs were isolated using the EXODUS platform, and gene expression was measured by RT-qPCR. Ten machine learning algorithms were evaluated for constructing the EGPS model with selected genes. Diagnostic efficacy was assessed by ROC analysis, DeLong tests, and decision curve analysis. An AI diagnostic system using DeepSeek was also developed. The EGPS model, incorporating AMACR, HOXB13, and PSGR, achieved AUCs of 0.838, 0.825, and 0.811 in the training, internal validation, and external validation cohorts, respectively, outperforming PSA. At a cut-off value of 0.22, the model demonstrated sensitivity above 95%, with a missed diagnosis rate of 3.81% in the training cohort and 0% in the validation cohorts. The model reduced unnecessary biopsies by 79 (23.37%), 27 (18.62%) and 9 (15.25%) cases across the three cohorts, thereby lowering biopsy-related risks. A DeepSeek-powered AI diagnostic system integrating EGPS was developed to support csPCa diagnosis and minimize unnecessary biopsies. EGPS, derived from multicentre Chinese cohorts, enables accurate, DRE-free, non-invasive prediction of csPCa in men with PSA levels of 0-15 ng/mL. When integrated into an AI system, EGPS supports early screening and personalized clinical decision-making by reducing unnecessary biopsies. - Source: PubMed
Jiang ShaoqinYang ChunguangHuang ZhangchengGuo ZebangLu FeitingNian XinwenChen ZhenlinLuo PengweiJiang JiaweiGao XuLi MengqiangLiu Fei